Precigen (STU:I5X) FFO


STU:I5X Precigen Inc STU:I5X
63 GF Score
Price €4.90
GF Value €5.33
Valuation Fairly Valued
! 10 Warning Signs
View Full Analysis

What is Precigen FFO?

FFO (Funds from operations) only applies to REITs.

STU:I5X
63GF Score
Precigen Inc STU:I5X
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Precigen (STU:I5X) Overvalued in 2026?

Based on GuruFocus' analysis, Precigen stock appears to be undervalued. The current stock price of €4.90 is trading 8.1% below its estimated GF Value™ of €5.33. GuruFocus considers Precigen to be Fairly Valued.

Key valuation signals for STU:I5X:

  • FFO:
  • GF Value™: €5.33 vs. price of €4.90 (8.1% below fair value)
  • GF Score™: 63/100 with 10 warning signs

No single metric tells the full story. See the STU:I5X stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Precigen Business Description

Other Exchanges PGEN:USA
Address 20374 Seneca Meadows Parkway, Germantown, MD, USA, 20876
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
63GF Score

Get the complete analysis for STU:I5X

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.90
Price
€5.33
GF Value